Zoetis Inc Stock Price, News & Analysis

Zoetis (NYSE:ZTS) announced the results of its 2021 Annual Meeting of Shareholders and declared a quarterly dividend of $0.25 per share, payable on Sept. 1, 2021. CEO Kristin Peck highlighted a 9% operational revenue growth and 10% adjusted net income growth in 2020, aided by strong cash flow. The company elected new directors and approved compensation packages for executives. Zoetis aims to maintain its growth trajectory with a focus on innovations in pet care, diagnostics, and international markets.

Zoetis (NYSE:ZTS) announced leadership changes aimed at enhancing its growth strategy. Effective June 1, 2021, Glenn David transitions from CFO to Executive Vice President and Group President, focusing on international operations and growth areas like aquaculture and pet insurance. Wetteny Joseph joins as CFO, bringing extensive financial expertise from Catalent. Both executives are expected to drive innovation and expand market presence, particularly in crucial regions like China and Brazil. These changes reflect Zoetis' commitment to sustained growth and maximizing shareholder value.

Zoetis reported strong Q1 2021 results with $1.9 billion in revenue, a 22% increase year-over-year. Net income rose 32% to $559 million, or $1.17 per diluted share. Adjusted net income was $603 million, up 33%. The company raised its full-year revenue guidance to $7.500-$7.625 billion, citing robust operational growth across its product segments, particularly in companion animal products, and successful sales in international markets. New product approvals and a recovering veterinary sector contributed to positive momentum. CEO Kristin Peck emphasized the company's diverse portfolio and commitment to innovation.

Zoetis (NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on May 6, 2021, to discuss its first quarter 2021 financial results. CEO Kristin Peck and CFO Glenn David will present the financial outcomes and address questions from analysts. Investors can access the live event via the Zoetis investor website, with a replay available post-event. In 2020, Zoetis generated $6.7 billion in revenue, emphasizing its position as a leading animal health company.

Summary not available.

Zoetis (NYSE:ZTS) is set to participate in the Cowen 41st Annual Health Care Conference on March 1, 2021. CEO Kristin Peck will present at 1:20 p.m. ET and answer questions from analysts. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations, with a replay available afterwards. As a leader in animal health, Zoetis generated $6.7 billion in revenue in 2020 and operates in over 100 countries, providing medicines, vaccines, and diagnostics for animal care.

Zoetis (NYSE:ZTS) will join the Bank of America Securities 2021 Animal Health Summit Virtual Forum on February 25, 2021. Glenn David, Executive Vice President and CFO, will present at 7:50 a.m. ET. Investors can listen to the live audio webcast at investor.zoetis.com/events-presentations, with a replay available post-event. Zoetis, a leader in animal health, reported $6.7 billion in annual revenue for 2020 and has a team of approximately 11,300 employees, providing essential products across over 100 countries.

Zoetis (NYSE:ZTS) has received marketing authorization from the European Commission for Solensia (frunevetmab), a groundbreaking treatment for feline osteoarthritis (OA). Affecting approximately 40% of cats, OA can severely impact their quality of life. Solensia is a monoclonal antibody that targets Nerve Growth Factor (NGF) to alleviate OA pain and is administered monthly by veterinarians. Clinical studies reveal that 76% of cat owners reported sustained improvements in their pets' pain symptoms, enhancing overall activity and sociability.

Zoetis Inc. (ZTS) reported Q4 2020 revenue of $1.8 billion, up 8% YoY, with net income of $359 million ($0.75/share). Adjusted net income was $438 million, relatively unchanged. Full-year revenue reached $6.7 billion, a 7% increase, with net income of $1.6 billion ($3.42/share). The company anticipates 2021 revenue growth of 9% to 11%, driven by strong performance in petcare and international markets. Key product approvals include Librela and Solensia for pain management in pets. Overall, Zoetis demonstrated resilience amidst COVID-19 challenges.